Mesh inlay, mesh kit or native tissue repair for women having repeat anterior or posterior prolapse surgery: randomised controlled trial (PROSPECT)
- PMID: 32141709
- DOI: 10.1111/1471-0528.16197
Mesh inlay, mesh kit or native tissue repair for women having repeat anterior or posterior prolapse surgery: randomised controlled trial (PROSPECT)
Abstract
Objective: To compare standard (native tissue) repair with synthetic mesh inlays or mesh kits.
Design: Randomised controlled trial.
Setting: Thirty-three UK hospitals.
Population: Women having surgery for recurrent prolapse.
Methods: Women recruited using remote randomisation.
Main outcome measures: Prolapse symptoms, condition-specific quality-of-life and serious adverse effects.
Results: A Mean Pelvic Organ Prolapse Symptom Score at 1 year was similar for each comparison (standard 6.6 versus mesh inlay 6.1, mean difference [MD] -0.41, 95% CI -2.92 to 2.11: standard 6.6 versus mesh kit 5.9, MD -1.21 , 95% CI -4.13 to 1.72) but the confidence intervals did not exclude a minimally important clinical difference. There was no evidence of difference in any other outcome measure at 1 or 2 years. Serious adverse events, excluding mesh exposure, were similar at 1 year (standard 7/55 [13%] versus mesh inlay 5/52 [10%], risk ratio [RR] 1.05 [0.66-1.68]: standard 3/25 [12%] versus mesh kit 3/46 [7%], RR 0.49 [0.11-2.16]). Cumulative mesh exposure rates over 2 years were 7/52 (13%) in the mesh inlay arm, of whom four women required surgical revision; and 4/46 in the mesh kit arm (9%), of whom two required surgical revision.
Conclusions: We did not find evidence of a difference in terms of prolapse symptoms from the use of mesh inlays or mesh kits in women undergoing repeat prolapse surgery. Although the sample size was too small to be conclusive, the results provide a substantive contribution to future meta-analysis.
Tweetable abstract: There is not enough evidence to support use of synthetic mesh inlay or mesh kits for repeat prolapse surgery.
Keywords: Pelvic organ prolapse; randomised controlled trial; repeat surgery; synthetic mesh.
© 2020 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.
Comment in
-
Management of recurrent pelvic organ prolapse.BJOG. 2020 Jul;127(8):1014. doi: 10.1111/1471-0528.16241. Epub 2020 May 7. BJOG. 2020. PMID: 32250520 No abstract available.
-
Re: Mesh inlay, mesh kit or native tissue repair for women having repeat anterior or posterior prolapse surgery: randomised controlled trial (PROSPECT).BJOG. 2020 Aug;127(9):1169-1170. doi: 10.1111/1471-0528.16301. Epub 2020 May 28. BJOG. 2020. PMID: 32468696 No abstract available.
References
-
- NICE Guideline [IPG599]. Transvaginal mesh repair of anterior or posterior vaginal wall prolapse. 2017 [www.nice.org.uk/guidance/ipg599]. Accessed 05 February 2019.
-
- Glazener C, Breeman S, Elders A, Hemming C, Cooper K, Freeman R, et al. Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery: two parallel-group, multicentre, randomised, controlled trials (PROSPECT). Lancet 2017;28:381-92.
-
- Olsen A, Smith V, Bergstrom J, Colling J, Clark A. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997;89:501-6.
-
- Toozs-Hobson P, Freeman R, Barber M, Maher C, Haylen B, Athanasiou S, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for reporting outcomes of surgical procedures for pelvic organ prolapse. Int Urogynecol J 2012;23:527-35.
-
- Maher C, Baessler K, Glazener CMA, Adams EJ, Hagen S. Surgical management of pelvic organ prolapse in women (withdrawn paper. 2007, art. no. CD004014). Cochrane Database Syst Rev 2007;(3):CD004014.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
